Omega 3 Supplementation in Children With Non Alcoholic Fatty Liver

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-03-01

Study Completion Date

2020-02-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

this is a prospective, interventional, open-label, randomized study on the efficacy of omega 3 fatty acids supplementation in Egyptian children with non-alcoholic fatty liver disease who had been selected from nutrition and outpatient clinic at Pediatric hospital, Ain Shams University

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Omega-3 Fatty Acids on Oxidative Stress and Dyslipidemia in Pediatric Patients Undergoing Hemodialysis

NCT02581449

End Stage Renal Disease

UNKNOWN PHASE2

Effect of Supplementation of Fish Oil on Non-alcoholic Fatty Liver Disease in Children

NCT01547910

Non-alcoholic Fatty Liver Disease

COMPLETED PHASE2

The Impact of Fish Oil Supplementation on the Outcome of Children with Pneumonia I

NCT06005454

Pneumonia

COMPLETED NA

Omega 3 Supplementation in Cystic Fibrosis Patients

NCT00959010

Cystic Fibrosis

COMPLETED PHASE3

Effects of Omega-3 Supplementation on Nutritional Status and Physical Activity of Obese Children

NCT04156971

Life Style Modification Childhood Obesity

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fatty Liver

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

supplemented

Life style modification, diet regimen and Omega-3 fatty acids supplementation

Group Type ACTIVE_COMPARATOR

omega 3 fatty acids

Intervention Type DIETARY_SUPPLEMENT

: Life style modification, diet regimen and Omega-3 fatty acids supplementation: The dose of omega-3 fatty acids depended on the weight of patients according to World Health Organization recommendations 400 milligrams per 10 kilograms of body weight and had been given into two doses per day, before morning and evening meals

non supplemented

Life style modification and diet regimen

Group Type ACTIVE_COMPARATOR

omega 3 fatty acids

Intervention Type DIETARY_SUPPLEMENT

: Life style modification, diet regimen and Omega-3 fatty acids supplementation: The dose of omega-3 fatty acids depended on the weight of patients according to World Health Organization recommendations 400 milligrams per 10 kilograms of body weight and had been given into two doses per day, before morning and evening meals

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

omega 3 fatty acids

: Life style modification, diet regimen and Omega-3 fatty acids supplementation: The dose of omega-3 fatty acids depended on the weight of patients according to World Health Organization recommendations 400 milligrams per 10 kilograms of body weight and had been given into two doses per day, before morning and evening meals

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Children between 5 - 16 years old with diffusely hyper echogenic liver at ultrasonography were included in the study.

Exclusion Criteria

* Patients with secondary causes of steatosis including total parenteral nutrition, drugs causing fatty liver disease for example steroids, hepatitis A, B, C, cytomegalovirus, Epstein-Barr virus infections, autoimmune liver disease, metabolic liver diseases, Wilson's disease, and alpha-1-antitrypsin deficiency.
* Patients currently taking fish oil supplements.
* Patients with systemic illness such as cardiac and kidney diseases.

Minimum Eligible Age

6 Years

Maximum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No